Narrative review / 2010
Grapefruit consumption is linked to potentially fatal drug interactions involving CYP3A4, while also offering benefits for diabetes and cardiovascular disorders.
This review evaluates metabolic and cardiovascular perspectives related to grapefruit consumption. Grapefruit or grapefruit juice consumption is associated with drug interactions—some fatal—mediated by intestinal CYP3A4, P-glycoprotein, and organic cation transporter proteins. Concurrently, grapefruit's rich flavonoid content has emerged as beneficial in managing degenerative conditions like diabetes and cardiovascular disorders, though the clinical extent of its drug interactions remains not fully determined.
- Study type
- Review
- Who was studied
- Not specified
- What was measured
- Drug interactions and metabolic/cardiovascular effects
THE PAPER
The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives.
Owira PM, Ojewole JA. Cardiovasc J Afr, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.